SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Bruce Rosen who wrote (1210)12/22/1997 1:08:00 AM
From: Bill Wexler  Respond to of 7041
 
Bruce, if you're going to keep telling lies about the company, how about some new ones? The old horsecrap is getting boring.

<<Owners of Zona last December were awaiting results of the Mexican trials. When they came back showing statistical significance, that eliminated a small part of the risk.>>

LOL!!! Yeah...the only thing that is "statistically significant" in this case is the fact that Zonagen is a fraud.

<<would say that the shorts have far more risk than the longs at these levels.>>

I can hardly wait to read what you have to say when the stock is another $10 a share lower.



To: Bruce Rosen who wrote (1210)12/22/1997 8:39:00 PM
From: BDR  Read Replies (1) | Respond to of 7041
 
<<Well, they have one patent with
another pending. The two together, it seems to me, will give them a strong patent
position. >>

Is there publicly accessible info on the second patent? I haven't found any. The first patent covers a mode of drug delivery for generic phentolamine, a mode that doesn't seem to my reading to apply to Vasomax.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News